- Lu-PSMA-617,[citation needed] sold
under the
brand name
Pluvicto, is a
radiopharmaceutical medication used for the
treatment of prostate-specific membrane...
- Radium-223
dichloride as the radioisotope, but its
ligand varies from
Pluvicto.
Pluvicto only
attacks cancer cells expressing PSMA, but
Xofigo attacks all...
-
numerous drug
discoveries and he is
credited as one of the
developers of
Pluvicto. He
cofounded the
biotechnology company Endocyte,
which was
later acquired...
- position. When the
radionuclides are
ligands (such as with
Lutathera and
Pluvicto), the
technique is also
known as
radioligand therapy. Iodine-131 (131I)...
- cancer". Teo,
Rathkopf &
Kantoff 2019, "Abiraterone acetate". "FDA
Approves Pluvicto for
Metastatic Castration-Resistant
Prostate Cancer". U.S. Food & Drug...
-
plitidepsin (INN)
plomestane (INN)
plovamer (USAN)
plusonermin pranosal (INN)
Pluvicto PMB.
Redirects to
Polymyxin B.
pobilukast (INN)
podilfen (INN) ****rilin...
-
radioligand therapy.
While lutetium-177 (177Lu)-PSMA-617 (approved as
Pluvicto) has
shown efficacy in mCRPC, some
patients are
resistant or
develop diffuse...
- is part of
their radiopharmaceutical portfolio,
alongside Lutathera and
Pluvicto. "lutetium lu 177-neob". My
Cancer Genome.
Retrieved 2025-05-21."[177Lu]-NeoB...
- (FDA) and
European Medical Authority (EMA)
registration of 177Lu-PSMA-617 (
Pluvicto) and 68Ga-PSMA-617 (Locametz) radio-therapeutic pair for the identification...
-
groundwork for the
eventual 2022
approval of Lu177
vipivotide tetraxetan (
Pluvicto®) for the
treatment of
prostate cancer.. His
recent research continues...
